ArticleAlzheimer's & dementia (Amsterdam, Netherlands)
Exploring the association between mild behavioral impairment and plasma p-tau217: Implications for early detection of Alzheimer's disease.
Article in Alzheimer's & dementia (Amsterdam, Netherlands). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- From Cerebrospinal Fluid to Blood Draw: Plasma p-Tau217 as a Non-Invasive Biomarker for Alzheimer's Disease: A Fagan Nomogram-Based Meta-Analytic Study.Molecular neurobiology · 2026Pooled it
- Tau-PET correlates of mild behavioral impairment in preclinical and prodromal Alzheimer's disease: A head-to-head comparison of Flortaucipir and MK6240.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Facial phenotypes in Alzheimer's disease: from neurobiology to artificial intelligence.Alzheimer's research & therapy · 2026Review
- Enhancing Alzheimer Disease Detection Using Neuropsychiatric Symptoms: The Role of Mild Behavioural Impairment in the Revised NIA-AA Research Framework.Journal of geriatric psychiatry and neurology · 2026Article
- Lifetime Exposure to Endogenous Estradiol and Markers of Dementia Risk: Associations with Later Life Cognitive, Behavioral, and Functional Complaints.Diagnostics (Basel, Switzerland) · 2026Article
- Elucidating the Neurobiological Underpinnings of Mild Behavioral Impairment in Tauopathies: Clinical and Molecular Insights.International journal of molecular sciences · 2026Review
- Neuropsychiatric symptoms in preclinical and clinically manifest dementia: clusters and their health determinants.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Persistent Functional Impairment as an Early Indicator of Alzheimer Disease Pathology and Progression.Journal of the American Geriatrics Society · 2026Article
- Reframing Dementia Prevention Strategies Aligned with the WHO Global Action Plan: A Structured Narrative Review Focusing on Mild Behavioral Impairment.Neurology international · 2026Review
- Therapeutic Advances in Targeting the Amyloid-β Pathway for Alzheimer's Disease.Brain sciences · 2025Review
- Exploring the association between mild behavioral impairment and plasma p-tau217: Implications for early detection of Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Associations among mild behavioral impairment, cognition, and brain pathology in preclinical autosomal dominant Alzheimer's disease.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- P-tau181 is longitudinally associated with a proxy measure of mild behavioral impairment among frail older adults: Insights from COGFRAIL.Alzheimer's & dementia (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
introductionMild behavioral impairment (MBI), marked by late-onset persistent neuropsychiatric symptoms (NPS), may signal early dementia risk. While MBI is linked to previously established amyloid-beta (Aβ) and tau biomarkers, its association with plasma p-tau217, a promising blood-based biomarker for Alzheimer's disease (AD), remains unexplored. Here, we investigated the association between MBI and plasma p-tau217 in dementia-free individuals from the Alzheimer's Disease Neuroimaging Initiative.
methodsMBI was defined using the Neuropsychiatric Inventory (NPI) data. Linear regression assessed the association between NPS status and continuous p-tau217 levels, while logistic regression modeled the association between NPS status and p-tau217 positivity, using a study-specific cutoff. Models adjusted for age, sex, education, and cognitive diagnosis.
resultsAmong 101 participants (mean age = 72.0 ± 6.5; 44.6% female), those with MBI had higher plasma p-tau217 levels ( DISCUSSION: Findings support the role of MBI in AD risk stratification. Highlights: Mild behavioral impairment (MBI) is linked to elevated plasma p-tau217, a specific Alzheimer's disease biomarker.MBI increases the odds of plasma p-tau217 positivity in dementia-free individuals.Findings support MBI as an early indicator for Alzheimer's disease risk.MBI assessment can improve biomarker-based screening and clinical trial efficiency.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.